Loading...
Market
Impact on COVID-19 vaccine market share post-Moderna patent victory
5
Resolution / Starting Odds
Increased Moderna market share • 33%
No significant change • 34%
Decreased Pfizer/BioNTech market share • 33%
Public announcements from vaccine distributors and healthcare providers
Story
Moderna Wins European Patent Dispute Against Pfizer, BioNTech Over COVID-19 Vaccine in Legal Battle
May 17, 2024, 10:30 PM
Moderna has emerged victorious in a European patent dispute against Pfizer and BioNTech over its COVID-19 vaccine. The European Patent Office upheld Moderna's key patent, marking a significant win in the ongoing legal battle with its rivals.
View original story
Similar markets
Moderna gains highest market share • 33%
Pfizer retains highest market share • 33%
BioNTech gains highest market share • 33%
Less than 10% • 25%
10% to 25% • 25%
25% to 50% • 25%
More than 50% • 25%
Novavax/Sanofi leads • 33%
Pfizer/BioNTech leads • 33%
Moderna leads • 33%
Less than 10% • 25%
10% - 20% • 25%
20% - 30% • 25%
More than 30% • 25%
Moderna performs best • 33%
Pfizer performs best • 33%
BioNTech performs best • 33%
Positive impact • 33%
Negative impact • 33%
No significant impact • 34%
Moderna most trusted • 33%
Pfizer most trusted • 33%
BioNTech most trusted • 33%
Pfizer • 25%
Moderna • 25%
Johnson & Johnson • 25%
Novavax • 25%
More than 20% • 50%
20% or less • 50%
Exceeds market expectations • 33%
Meets market expectations • 34%
Falls below market expectations • 33%
Becomes a top 5 vaccine company • 25%
Remains outside top 5 but improves position • 25%
No significant change in market position • 25%
Declines in market position • 25%